Payer pushback aside, Sovaldi, and so Gilead, has another huge quarter

Eric Palmer Gilead Sciences' juggernaut, Sovaldi, keeps on rolling along despite the pushback from payers, politicians and health officials over the high price of the hepatitis ...

UPDATED: Gilead picks up blockbuster FDA blood cancer approvals for idelalisib

John Carroll Gilead said today that the FDA has approved its PI3k inhibitor idelalisib for three types of B-cell blood cancers following its early Phase III success last fall on impressive ...

$9.9M ‘golden hello’ awaits Shire chief Ornskov at new AbbVie post

Carly Helfand When AbbVie buys out Shire for nearly $ 55 billion in a deal the two companies agreed on last week, there will be no golden parachute awaiting Shire chief Flemming Ornskov. ...

Shire inks a $225M rare disease deal on the eve of life with AbbVie

Damian Garde Shire has signed a $ 225 million agreement to brighten its future in rare diseases, bolstering a major selling point for AbbVie as the two prepare for a $ 54.7 billion ...

News flash for biopharma bosses: More than half your employees want to leave

Carly Helfand Biopharma employee looking for a new job? You're not alone. In fact, you're not even in the minority, a new report says. FiercePharma News

Cost-conscious payers are eyeing higher prices on diabetes drugs

Tracy Staton A time-honored technique for boosting drug sales is simple: Raise prices. Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable ...

Tuberculosis cocktail stirs hopes for quick cures in patients with HIV

Damian Garde A new three-drug combo treatment for tuberculosis better eradicated the disease than standard therapy in a midstage trial, showing particular promise for patients with ...

Puma shares triple on positive PhIII neratinib data, plans to file for approval

John Carroll FierceBiotech News

Avastin nabs second-in-a-row priority review, this time in ovarian cancer

Tracy Staton Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. FiercePharma News

With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia

Damian Garde Scientists from the Broad Institute are unveiling new genomic findings from thousands of schizophrenia patients that could lead to new molecular targets. And, thanks to ...

Pharma peer pressure makes tax-friendly M&A targets the new must-have

Tracy Staton Talk about peer pressure. First, a couple of U.S. drugmakers pull off trans-Atlantic deals that shift their official HQs and lower their tax rates. Next, some bigger names ...

Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic

John Carroll This morning Atlas Venture and New Enterprise Associates announced that they have committed $ 29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS